Gopal Sapkota's Research Group

Sapkota Lab Website | Pubmed | Biography

Understanding mechanisms of reversible phosphorylation and ubiquitylation in cell signalling and disease.

Reversible phosphorylation and ubiquitylation of proteins underpin the regulation of many cell signalling processes. Faulty signalling cascades account for many human diseases, including skin and bone disorders, cancer and neurodegenerative diseases.

Our group focusses on two key areas of research:

A: FAM83 family as key regulators CK1 isoforms: The CK1 family of constitutively active protein kinases controls a plethora of cellular processes and their misregulation is associated with many human diseases, yet the regulation of CK1 activity, substrate specificity, subcellular localisation and turnover are still understood poorly. Building on our recent discoveries, the research in our group is exploring the hypothesis that the family of FAM83 proteins are key regulators of CK1 isoforms, which act by directing specific CK1 isoforms to distinct subcellular compartments and substrates. We have shown that FAM83G (aka PAWS1) mediates Wnt signalling through association with CK1α. Moreover, pathogenic PAWS1 mutations that cause palmoplantar hyperkeratosis are unable to interact with CK1α, and consequently fail to mediate Wnt signalling. We have also shown that FAM83D directs CK1α to the mitotic spindle to ensure proper spindle positioning and timely cell division.

We aim to continue to dissect the roles of FAM83 proteins in CK1 biology and human diseases. Some key research objectives are:

  1. Understand the molecular basis of FAM83-CK1 interaction.
  2. Identify, and characterise the roles of, PAWS1-dependent CK1α substrates in Wnt signalling and FAM83D-dependent CK1α substrates in mitosis.
  3. Delineate the molecular mechanisms by which other FAM83 proteins direct specific CK1 isoforms to specific subcellular compartments and substrates in response to different signalling cues.

B: Harnessing the ubiquitin proteasome system for drug discovery: Efficient targeted proteolysis of endogenous proteins is desirable in therapeutics and as a research toolkit. Gene knockouts are irreversible and, for many proteins, not feasible. Similarly, RNA interference approaches necessitate prolonged treatments, can lead to incomplete knockdowns and are often associated with off-target effects. Direct proteolysis of target proteins can overcome these limitations. Our lab has developed the Affinity-directed PROtein Missile (AdPROM) System to target endogenous proteins for efficient degradation. We aim to develop this system further to engineer highly efficient inducible AdPROM as well as adapt it to rapidly establish the best E3 ligases for most efficient degradation of target proteins. We want to exploit AdPROM to rapidly test the druggability of so-called “undruggable” targets by proteolysis. We will also explore the therapeutic potential of AdPROM in clearing misfolded proteins that are hallmarks of many neurodegenerative diseases.

Back row (L-R): Gajanan Sathe, Pax Zhang, Gopal Sapkota, Tyrell Cartwright, Ellie Leeder, Naveen Kumar Nakarakanti. Front Row (L-R) Nur Kocaturk, Abigail Brewer, Jin-Feng Zhao, Preethi Soundarya Sathyamurthi, Lorraine Glennie
Back row (L-R): Gajanan Sathe, Pax Zhang, Gopal Sapkota, Tyrell Cartwright, Ellie Leeder, Naveen Kumar Nakarakanti. Front Row (L-R) Nur Kocaturk, Abigail Brewer, Jin-Feng Zhao, Preethi Soundarya Sathyamurthi, Lorraine Glennie


Ellie Leeder | Visiting MSc Student
Katy Clarke | Undergraduate Honours Student
Shing Yan Adrian Wu | MSc Student
Abigail Brewer | PhD Student
Dr Tyrell Cartwright | Postdoctoral Researcher
Lorraine Glennie | PhD Rotation Student
Naveen Kumar Nakarakanti | Postdoctoral Researcher
Gajanan Sathe | Postdoctoral Researcher
Jin-Feng Zhao | Postdoctoral Researcher

Selected Publications

  • Dunbar K, Jones RA, Dingwell K, Macartney TJ, Smith JC, Sapkota GP (2020) FAM83F regulates canonical Wnt signalling through an interaction with CK1α Life Sci Alliance 4(2) e202000805 doi:10.26508/lsa.202000805 PMID: 33361109
  • Dunbar K, Macartney TJ, Sapkota GP (2021) IMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling Life Sci Alliance 4 (2) e202000804. doi: 10.26508/lsa.202000804 doi:10.26508/lsa.202000804 PMID: 33361334
  • Simpson LM, Macartney TJ, Nardin A, Fulcher LJ, Röth S, Testa A, Maniaci C, Ciulli A, Ganley IG, Sapkota GP (2020) Inducible Degradation of Target Proteins through a Tractable Affinity-Directed Protein Missile System Cell Chem Biol 27 1165-1180 PMID: 32668203
  • Röth S, Macartney TJ, Konopacka A, Chan KH, Zhou H, Queisser MA, Sapkota GP (2020) Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System Cell Chem Biol 27 1151-1163 PMID: 32668202
  • Fulcher, L. J., He, Z., Mei, L., Macartney, T. J., Wood, N., Prescott, A. R., Whigham, A., Varghese, J., Gourlay, R., Ball, G., Clarke, R. G., Campbell, D. G., Maxwell, C. A., and Sapkota G. P. (2019) FAM83D directs protein kinase CK1α to the mitotic spindle for proper spindle positioning. EMBO 20 e47495 PMID: 31338967
  • Fulcher, L. J., Bozatzi, P., Tachie-Menson, T., Cummins, T. D., Wu, K., Dunbar, K., Shrestha, S., Wood, N., Weidlich, S., Macartney, T. J., Varghese, J., Gourlay, R., Campbell, D. G., Dingwell, K. S., Smith, J. C., Bullock, A., and Sapkota, G. P. (2018) The DUF1669 domain of FAM83 family proteins anchor Casein Kinase 1 isoforms. Sci signalling 11:531 eaao2341 DOI: 10.1126/scisignal.aao2341 PMID: 29789297
  • Kevin Z L Wu, Rebecca A Jones, Theresa Tachie-Menson, Thomas J Macartney, Nicola T Wood, Joby Varghese, Robert Gourlay, Renata F Soares, James C Smith and Gopal P Sapkota (2019) Pathogenic FAM83G palmoplantar keratoderma mutations inhibit the PAWS1:CK1a association and attenuate Wnt signalling  4 133
  • Bozatzi P, Dingwell KS, Wu KZ, Cooper F, Cummins TD, Hutchinson LD, Vogt J, Wood NT, Macartney TJ, Varghese J, Gourlay R, Campbell DG1, Smith JC, Sapkota GP (2018) PAWS1 controls Wnt signalling through association with casein kinase 1α EMBO Rep. 19(4) pii: e44807 PMID: 29514862